Barrons·Jun 18, 2026
Living Longer Is Big Business. These Stocks Will Benefit.TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
Guardant Health, Inc.(GH)Earnings, Financials & Key Ratios
GH•NASDAQ
$162.92
Price updated Jul 7, 2026
AboutGuardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.Show more
- Revenue$982M+32.9%
- EBITDA-$397M+1.2%
- Net Income-$416M+4.6%
- EPS (Diluted)-3.32+6.7%
- Gross Margin64.46%+6.0%
- EBITDA Margin-40.38%+25.6%
- Operating Margin-44.43%+26.0%
- Net Margin-42.39%+28.2%
GH Price & Volume
Guardant Health, Inc. (GH) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Revenue Growth Faces Structural Profitability Headwinds
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Accelerating
Profitability:Negative
Financial:Strained
Cash Flow:Burning
Primary Risk:High Cash Burn Rate
Key Thesis Takeaways
- Guardant Health is currently navigating a high-growth phase characterized by a 48.3% revenue increase in 2026Q1, yet this expansion is heavily reliant on aggressive commercial spending that continues to outpace gross profit.
- The company's reliance on $47.6M in quarterly stock-based compensation and a mounting $1.7B debt load suggests significant long-term solvency risks.
- Investors should monitor whether the Shield screening platform can achieve sufficient scale to offset the persistent negative operating margins of -40.2% and stabilize the company's deteriorating equity base.
Verdict Logic
the company's reliance on $47.6M in quarterly stock-based compensation to mask operational losses, combined with a negative equity position of -$181.1M, suggests an unsustainable path toward long-term profitability.
GH Growth Metrics
Guardant Health, Inc. (GH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years27.92%
3 Years29.75%
TTM39.56%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM0%
Return on Capital
10 Years-27.79%
5 Years-29.91%
3 Years-32.76%
Last Year-29.37%
GH Recent Earnings
Guardant Health, Inc. (GH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.85-5.5%
$0.81
Rev
$302M+8.1%
$279M
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$0.90-17.4%
$0.77
Rev
$281M+3.2%
$272M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.39+18.8%
$0.48
Rev
$265M-0.9%
$268M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.44+15.4%
$0.52
Rev
$232M-1.5%
$236M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.85vs $0.81-5.5% | $302Mvs $279M+8.1% |
| Q1 2026 | Feb 19, 2026 | $0.90vs $0.77-17.4% | $281Mvs $272M+3.2% |
| Q4 2025 | Oct 29, 2025 | $0.39vs $0.48+18.8% | $265Mvs $268M-0.9% |
| Q3 2025 | Jul 30, 2025 | $0.44vs $0.52+15.4% | $232Mvs $236M-1.5% |
Based on last 12 quarters of dataView full earnings history →
Latest GH News
Recent stock market news and headlines for Guardant Health, Inc. (GH)
Peers Comparison
Key metrics vs top competitors for Guardant Health, Inc. (GH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $162.92 | $21.6B | -49.07 | 32.88% | -42.39% | — | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $191.76 | $29.13B | 35.19 | -0.78% | 19.43% | 32.84% | — | |
| $281.27 | $40.28B | -185.05 | 35.9% | -9.05% | -15.13% | — | |
| $12.82 | $670.16M | -5.30 | 230194.59% | -182.34% | -36.83% | — | |
| $2.39 | $225.98M | 6.29 | 161.14% | 48.57% | 55.68% | — |
Compare GH vs Peers
Guardant Health, Inc. (GH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GH SEC Filings & Documents
Guardant Health, Inc. (GH) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Feb 19, 2026·SEC
10-K Annual Reports
1FY 2026
Feb 19, 2026·SEC
10-Q Quarterly Reports
4Get notified when GH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GH Frequently Asked Questions
Guardant Health, Inc. (GH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Guardant Health, Inc.'s revenue?
Guardant Health, Inc. (GH) reported $1.08B in revenue for fiscal year 2025. This represents a 4178% increase from $25.2M in 2016.
How fast is Guardant Health, Inc. growing?
Guardant Health, Inc. (GH) grew revenue by 32.9% over the past year. This is strong growth.
Is GH profitable?
Guardant Health, Inc. (GH) reported a net loss of $433.2M for fiscal year 2025.
Dividend & Returns
What is Guardant Health, Inc.'s free cash flow?
Guardant Health, Inc. (GH) had negative free cash flow of $224.8M in fiscal year 2025, likely due to heavy capital investments.